Reaction

Nocardiosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,529 reports · 102 co-occurring drugs

As of the last recalculation, Nocardiosis appears in 2,529 FAERS reports alongside 102 co-occurring drug terms. The strongest observed disproportionality signal is VALGANCICLOVIR HYDROCHLORIDE POWDER, (PRR 112.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Valganciclovir Hydrochloride Powder,	157	112.9	114.4
Tacrolimus Ointment 0.1%	939	98.1	98.9
Tacrolimus Extended-Release Capsules	939	97.9	98.6
Atovaquone	91	96.5	97.6
Tacrolimus	987	84.4	85.0
Valganciclovir	172	80.5	81.2
Valganciclovir Hydrochloride	172	80.5	81.2
Mycophenilic Acid	147	61.9	62.4
Mycophenolate Mofetil	590	46.3	46.5
Mycophenolate Mofetil Hydrochloride	590	46.2	46.4
Mycophenolic Acid	154	42.1	42.3
Basiliximab	53	37.9	38.0
Minocycline	50	36.0	36.1
Sirolimus	57	35.6	35.7
Anti-Thymocyte Globulin (Rabbit)	34	35.1	35.3
Daspone	38	32.6	32.7
Dapsone Gel, 5%	38	32.6	32.7
Prednisolone	550	31.8	31.9
Prednisolone Oral	550	31.8	31.9
Prednisolone Oral Solution	550	31.8	31.9
Linezolid	104	29.9	30.0
Dapsone	38	29.7	29.8
Amikacin	59	29.1	29.2
Ceftriaxone	107	28.0	28.1
Alemtuzumab	64	27.9	28.0
Meropenem	97	25.8	25.9
Posaconazole Delayed-Release	34	25.8	25.9
Ceftriaxone Sodium	108	24.2	24.2
Methylprednisolone	342	23.4	23.4
Moxifloxacin	38	22.5	22.6
Prednisone	888	21.9	21.9
Ampicillin	21	21.0	21.1
Ampicillin Sodium	21	21.0	21.1
Voriconazole Injection	50	19.3	19.4
Thiotepa	22	19.1	19.2
Posaconazole	35	18.0	18.0
Itraconazole	24	17.1	17.1
Busulfan	32	16.9	17.0
Moxifloxacin Hydrochloride	39	16.1	16.1
Voriconazole	56	15.5	15.5
Azathioprine	155	15.4	15.4
Cefepime	26	15.1	15.1
Cefepime Hydrochloride	28	14.5	14.5
Rifampicin	17	13.9	13.9
Ganciclovir Sodium	16	12.5	12.5
Cyclosporine	158	12.4	12.4
Ganciclovir	15	12.1	12.1
Chlorthalidone	16	11.4	11.4
Fludarabine Phosphate	51	10.9	10.9
Nystatin Ointment	34	10.8	10.8
Nystatin Cream	34	10.8	10.8
Isoniazid	21	10.7	10.8
Nystatin	34	10.4	10.4
Methylprednisolone Acetate	10	10.3	10.3
Cyclophosphamide Injection, Solution	197	9.8	9.9
Cyclophosphamide	197	9.8	9.9
Cyclophosphamide For Injection	197	9.8	9.9
Hydroxychloroquine	85	9.7	9.7
Vancomycin	66	9.6	9.6
Fluconazole	79	9.5	9.6
Sulfamethoxazole And Trimethoprim	94	9.5	9.5
Tofacitinib Citrate	15	9.5	9.5
Mesna Injection	9	9.0	9.0
Vancomycin Hydrochloride	70	9.0	9.0
Mesna	9	8.8	8.8
Melphalan	24	8.8	8.8
Levofloxacin	58	8.1	8.1
Levofloxacin In 5% Dextrose	58	8.1	8.1
Bendamustine Hcl	15	8.0	8.0
Melphalan Hydrochloride	24	7.9	8.0
Cladribine	9	7.7	7.7
Amphotericin B	11	7.3	7.3
Piperacillin And Tazobactam	11	7.1	7.1
Temozolomide	18	7.1	7.1
Thalidomide	30	6.8	6.8
Clarithromycin	27	6.5	6.5
Ursosiol	15	6.4	6.4
Cefazolin	7	6.3	6.3
Rifampin	11	6.2	6.2
Oseltamivir	6	6.2	6.2
Rituximab	148	6.1	6.1
Piperacillin Sodium,Tazobactam Sodium	19	5.9	5.9
Mercaptopurine	12	5.7	5.7
Ursodiol	15	5.7	5.7
Micafungin Sodium	5	4.9	4.9
Bendamustine Hydrochloride	7	4.8	4.8
Valacyclovir	24	4.8	4.8
Ruxolitinib	41	4.8	4.8
Imatinib	10	4.7	4.7
Carfilzomib	16	4.7	4.7
Bortezomib	48	4.5	4.5
Dexamethasone 1.5 Mg	149	4.4	4.4
Dexamethasone	149	4.3	4.3
Apixaban	34	4.2	4.2
Etoposide	36	4.1	4.1
Bleomycin Sulfate	5	4.0	4.0
Belimumab	14	3.7	3.7
Ixazomib	10	2.9	2.9
Daratumumab	13	2.7	2.7
Eltrombopag Olamine	7	2.5	2.5
Remdesivir	4	2.5	2.5
Abiraterone	4	2.4	2.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.